This filing contains no material financial or operational data — it is a routine annual meeting report. The authorization to issue shares and increase authorized capital is standard and does not indicate imminent dilution. No trading action warranted.
Price Chart
Executive Summary
ProQR Therapeutics filed a 6-K reporting the results of its 2026 annual general meeting of shareholders held on June 2, 2026. All agenda items were approved, including adoption of 2025 annual accounts, appointment of a new non-executive director, re-appointment of KPMG as auditor, amendment of articles to increase authorized capital, and authorization for the board to issue and repurchase shares. The board committees were also reconstituted. This is a routine governance filing with no material financial or operational news.
Key Facts
- Annual general meeting held June 2, 2026; all agenda items approved by shareholders.
- Adoption of 2025 annual accounts approved with 99.7% of votes in favor.
- Appointment of Dr. Lykke Hinsch Gylvin as non-executive director approved with 99.7% of votes.
- KPMG Accountants N.V. appointed as external auditor for fiscal year 2027 with 99.8% approval.
- Amendment of Articles of Association to increase authorized capital approved with 65.4% of votes.
- Board authorized to issue ordinary shares (64.3% approval) and to repurchase ordinary shares (66.7% approval).
- Board committees reconstituted: Audit, Compensation/Nominating/Governance, and R&D committees.
Financial Impact
No financial figures disclosed; governance items only.
Risk Factors
- Authorization to issue shares could lead to future dilution if exercised, but no current plan disclosed.
- Share repurchase authorization does not obligate the company to buy back shares.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-069450 |
| Document: 0001104659-26-069450-index-headers.html | 0001104659-26-069450 |
| Document: 0001104659-26-069450-index.html | 0001104659-26-069450 |
| Document: 0001104659-26-069450.txt | 0001104659-26-069450 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | 6-K | $1.70 $1.66 | ▼ −2.35% | ▼ −1.68% | $1.34 (−21.18%) |
Sep 9, 2026 6w ago | 6-K | $1.99 $1.86 | ▼ −6.53% | ▼ −5.44% | $1.34 (−32.66%) |
Jul 16, 2026 14w ago | EFFECT | $1.67 $1.79 | ▼ −7.19% | ▼ −8.86% | $1.34 (+19.76%) |
Jun 25, 2026 17w ago | 6-K | $1.53 $1.81 | ▼ −18.30% | ▼ −16.13% | $1.34 (+12.42%) |
Jun 25, 2026 17w ago | 424B5 | $1.53 $1.81 | ▲ +18.30% | ▲ +16.13% | $1.34 (−12.42%) |
Jun 2, 2026 21w ago | 6-K | $1.47 $1.41 | ▼ −4.08% | ▼ −0.26% | $1.34 (−8.84%) |
May 12, 2026 24w ago | 6-K | $1.60 $1.51 | ▲ +5.63% | ▲ +5.70% | $1.34 (+16.25%) |
Apr 30, 2026 25w ago | 6-K | $1.57 $1.72 | ▲ +9.55% | ▲ +7.83% | $1.34 (−14.65%) |
Apr 30, 2026 25w ago | Press Release | $1.57 $1.72 | ▲ +9.55% | ▲ +7.83% | $1.34 (−14.65%) |
Apr 8, 2026 28w ago | 6-K | $1.98 $1.95 | ▼ −1.52% | ▼ −4.70% | $1.34 (−32.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers